New drug combination targets rare childhood leukemia that resists standard treatment

This trial tests whether adding the drug revumenib to standard chemotherapy (fludarabine and cytarabine) can help children and young adults with a rare form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The study enrolls up to 27 participants aged 30 days to 22 years who have a specific genetic change called NUP98 rearrangement. Participants receive up to two cycles of the drug combination, and some may also receive a stem cell transplant followed by revumenib alone. The main goal is to see how many patients achieve remission after treatment.